Geode Capital Management LLC bought a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 201,748 shares of the company's stock, valued at approximately $4,133,000. Geode Capital Management LLC owned about 0.55% of Rapport Therapeutics at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. acquired a new position in shares of Rapport Therapeutics during the 3rd quarter valued at about $1,498,000. Millennium Management LLC acquired a new position in Rapport Therapeutics during the second quarter worth approximately $2,716,000. Perceptive Advisors LLC purchased a new position in Rapport Therapeutics during the second quarter worth approximately $17,403,000. ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics in the 2nd quarter valued at $86,730,000. Finally, TD Asset Management Inc purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at $2,361,000.
Rapport Therapeutics Trading Down 7.6 %
Shares of RAPP traded down $1.49 during trading hours on Monday, hitting $17.99. The stock had a trading volume of 61,156 shares, compared to its average volume of 85,552. Rapport Therapeutics has a 12-month low of $16.55 and a 12-month high of $29.74. The stock has a fifty day simple moving average of $21.36.
Rapport Therapeutics Company Profile
(
Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
